HHS Updates National Alzheimer’s and Dementia Plan
HHS advances Alzheimer’s research through drug repurposing and platform trials
The U.S. Department of Health and Human Services (HHS) has updated the National Plan to Address Alzheimer’s Disease and Related Dementias, shifting its focus toward prevention, earlier detection and the development of new treatments.
The revised plan replaces six previous goals with four priorities: reducing dementia risk, accelerating prevention and treatment research, improving dementia care, and strengthening support for caregivers.
The announcement includes several federal initiatives, highlighted by up to $48.8 million in combined funding from the Advanced Research Projects Agency for Health (ARPA-H) for projects focused on Alzheimer’s research.
Platform Trial to Test Potential Treatments
The largest investment, up to $41 million, will support Mass General Brigham researchers in leading a multi-institutional Alzheimer’s disease platform trial.
The study will evaluate whether existing drugs approved for other conditions could be repurposed to treat Alzheimer’s. Researchers will also investigate supplements, plant-derived products and other compounds as potential therapies.
ARPA-H is providing an additional $2.75 million to support research at the University of California, San Francisco. The project will complement existing work examining sleep-related risks and early protein dysfunction associated with Alzheimer’s disease.
FDA Launches Alzheimer’s Prevention Initiative
The Food and Drug Administration (FDA) also announced the launch of its Alzheimer’s Prevention Accelerator, part of a new agency program called the Neuroscience Advancement and Innovation Nexus.
The initiative aims to encourage new approaches to preventing or delaying cognitive decline associated with Alzheimer’s disease and accelerate the development of potential medical products.
Other federal efforts will expand brain health resources and dementia training for professionals working with older adults, including lawyers and social workers who help prevent elder abuse and financial exploitation.
Additional initiatives will focus on dementia screening, behavioral health and crisis response resources, public health strategies, diagnostic delays and the economic impact of dementia.
The plan also includes reviewing evidence on dementia prevention and testing a lifestyle intervention for people with mild cognitive impairment.
The Alzheimer’s Association welcomed the administration’s emphasis on research and innovation, while emphasizing that advances must translate into accessible care.
The organization also pointed to proposed bipartisan legislation, the Alzheimer’s Screening and Prevention (ASAP) Act, as an opportunity to expand Medicare beneficiaries’ access to advances in blood-based biomarker testing.
The updated plan reflects a broader federal effort to move Alzheimer’s care beyond treatment of established disease toward earlier identification, prevention research and improved support for patients and caregivers.
This version keeps the focus on federal healthcare policy, research investment, treatment development and implications for healthcare leaders while removing repetition and secondary detail.
